Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Phase 1

Withdrawn

Conditions: Primary Peritoneal Carcinoma
Ovarian Carcinoma, Stage 3 or 4
Epithelial Ovarian Carcinoma

Interventions: Drug: Paclitaxel
Drug: N-acetylcysteine
Drug: Cisplatin

First Posted Date: 2010-06-07

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT01138137

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Breakthrough Nausea and Vomiting

Interventions: Drug: fosaprepitant dimeglumine
Drug: systemic chemotherapy
Other: survey administration
Procedure: quality-of-life assessment

First Posted Date: 2009-12-15

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 34

Registration Number: NCT01031953

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: imatinib mesylate
Drug: methotrexate
Drug: methylprednisolone
Drug: pegaspargase
Drug: vincristine sulfate

First Posted Date: 2009-11-01

Last Posted Date: 2023-01-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01005914

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response

Terminated

Conditions: Head and Neck Cancer

First Posted Date: 2009-10-14

Last Posted Date: 2016-03-25

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00994201

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Phase 1

Conditions: Germ Cell Tumor
Recurrent Medulloblastoma
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Medulloblastoma
Medulloepithelioma
Recurrent Malignant Germ Cell Tumor
Recurrent Primitive Neuroectodermal Tumor
Primitive Neuroectodermal Tumor
Central Nervous System Embryonal Neoplasm
Recurrent Childhood Central Nervous System Embryonal Neoplasm

Interventions: Drug: Carboplatin
Drug: Mannitol
Drug: Melphalan
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sodium Thiosulfate

First Posted Date: 2009-09-24

Last Posted Date: 2021-10-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00983398

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Early Phase 1

Completed

Conditions: Recurrent Childhood Brain Neoplasm
Childhood Brain Neoplasm

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol Non-Stoichiometric Magnetite
Drug: Gadolinium

First Posted Date: 2009-09-17

Last Posted Date: 2022-08-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00978562

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Tissue Sample Collection From Patients With Fanconi Anemia

Completed

Conditions: Fanconi Anemia
Unspecified Childhood Solid Tumor, Protocol Specific
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2009-05-12

Last Posted Date: 2017-12-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00899522

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Breast Cancer
Gestational Trophoblastic Tumor
Nausea and Vomiting
Ovarian Cancer
Chronic Myeloproliferative Disorders
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2009-05-12

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00900068

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants

Terminated

Conditions: Fanconi Anemia

First Posted Date: 2009-05-12

Last Posted Date: 2017-12-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 90

Registration Number: NCT00896740

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Completed

Conditions: Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2016-02-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 98

Registration Number: NCT00900302

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy